Burning Rock Biotech Limited (BNR)
After hours:
| Previous close | 3.1700 |
| Open | 3.2300 |
| Bid | 3.1000 x 800 |
| Ask | 3.4500 x 900 |
| Day's range | 3.0800 - 3.2500 |
| 52-week range | 1.7000 - 11.2700 |
| Volume | |
| Avg. volume | 225,095 |
| Market cap | 339.377M |
| Beta (5Y monthly) | 0.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2680 |
| Earnings date | 20 Mar 2023 - 24 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.81 |
- GlobeNewswire
Burning Rock provides an update on 2022 revenue guidance
GUANGZHOU, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it expects the Company’s full-year revenue growth for 2022 to be approximately 10% compared to that of 2021. This represents an upward revision compared with the Company’s previous guidance on the full-year revenue gr
- Simply Wall St.
Even after rising 28% this past week, Burning Rock Biotech (NASDAQ:BNR) shareholders are still down 63% over the past year
It is doubtless a positive to see that the Burning Rock Biotech Limited ( NASDAQ:BNR ) share price has gained some 47...
- GlobeNewswire
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
IRVINE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA), which is the third of its kind globally. Under the FDA’s Breakthrough Devices Program, the Breakthrough Device Designation is gra
